Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Bearish flow noted in Bristol Myers (BMY) Squibb with 6,501 puts trading, or 1.1x expected. Most active are Nov-24 59 puts and 11/29 weekly 50 puts, with total volume in those strikes near 3,400 ...
Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA and the ...
With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...
Application error: a client-side exception has occurred (see the browser console for more information).
If you’re on the fence about investing in Bristol-Myers Squibb Co or Novo Nordisk A/S (ADR) because you’re not sure how they measure up, it’s important to compare them on a few factors before making ...
Bristol Myers Squibb is lifting its 2024 financial guidance for the second straight quarter as CEO Chris Boerner’s “transition period” continues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback